Kornimate/medical-research-clean huggingface dataset:
correlation between serum uric acid and pulmonary hypertension in obstructive sleep apnea syndrome

Conditions: Obstructive Sleep Apnea

Summary: this study aimed to correlate serum uric acid levels and pah in osahs patients.

obstructive sleep apnea-hypopnea syndrome is the most common form of srbds. recurrent hypoxia, that accompanies osahs increases the degradation of atp, which in turn increase uric acid concentration that can be used as a biomarker of tissue hypoxia in osahs. there is still debate about whether osahs is an independent contributor to pulmonary arterial hypertension. aim of the work this study aimed to correlate serum uric acid levels and pah in osahs patients. methods we enrolled 100 patients diagnosed with osahs using polysomnography. patients were divided into three severity groups: mild osa (5 ≤ ahi \< 15), moderate osa (15 ≤ ahi \< 30), and severe (30 ≤ ahi \< 60). serum uric acid was measured the morning after polysomnography. all patients underwent standard echocardiograms, and pulmonary artery systolic pressure calculation was done.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of osahs by overnight polysomnography (ahi ≥ 5/ hr) * ≥18 years old. exclusion criteria: * other sleep disorders as narcolepsy or hypersomnia were excluded as well as patients with neuropsychiatric disorders. * hemodynamically unstable patients * patients with other chronic respiratory or cardiac diseases * patients with other known causes of pulmonary hypertension * patients with any disease or on medication that could alter excretion or urinary metabolism of uric acid such as excessive uric acid production
hd mapping of atrial fibrillation in asia pacific

Conditions: Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation

Summary: the aim of this study is to quantify and characterize the outcomes of radiofrequency (rf) ablation after, and the utility of, electroanatomical mapping with the market-released hd mapping catheters inquiry™ afocusii™ double loop and advisor™ hd grid, sensor enabled™ with the ensite cardiac mapping system and the ensite automap module in subjects with af in the real-world environment of the asian population.


Eligibility criteria:
inclusion criteria: 1. subject must provide written informed consent for study participation and willing and able to comply with the protocol described evaluations and follow up schedule 2. subject must be over 18 years of age. (in japan, the subject must be of 20 years of age or older) 3. subject is diagnosed with af as defined by: * documented symptomatic paroxysmal af defined as af that terminates spontaneously or with intervention within 7 days of onset * documented symptomatic persistent af defined as continuous atrial fibrillation that is sustained beyond 7 days but less than 12 months 4. subject is indicated for cardiac electroanatomical mapping and rf ablation procedure to treat af 5. subject is planned to have electroanatomical mapping performed with the hd mapping catheters under investigation exclusion criteria: 1. previous ablation or surgery in the left atria 2. implanted left atrial appendage occluder 3. implanted mitral or tricuspid valve replacement 4. implanted cardiac defibrillator (icd) 5. participation in another clinical investigation that may confound the results of this study 6. pregnant or nursing 7. presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results. 8. life expectancy less than 12 months
does endorphin massage reduce the anxiety of pregnant women?

Conditions: Pregnancy Related

Summary: before cesarean section surgery, researchers will demonstrate endorphin massage to the husbands of pregnant women, and they will be asked to apply the massage before the surgery. the stress levels and pain levels of women will be compared before and after the massage.

the sample size of the research was calculated using g\*power 3.1.9.4 software as a minimum of 34 with 95% power, 0.01 alpha, and 0.9 effect size. the sample size was planned as experimental (n=34) and control (n=34) groups. to ensure the equality of the samples in both groups, a simple randomization method was used, where pregnant women with odd hospital protocol numbers will be included in the experimental group and those with even numbers will be included in the control group. pregnant women who are admitted for pre-cesarean section care will be informed about the study, and their voluntary consent will be obtained both in written and verbal form. pre-tests will be administered to both the experimental and control groups at 08:00, and blood samples will be taken to measure cortisol levels. subsequently, an intervention will be applied to those in the experimental group, while those in the control group will receive routine nursing care. at 09:00, post-tests will be administered to both the experimental and control groups, and blood samples will be taken again to measure cortisol levels. the pre-test and post-test results, as well as the mean cortisol levels, will be compared between the experimental and control groups.

Eligibility criteria:
inclusion criteria: * being admitted to the hospital for cesarean section * being willing to participate in the research exclusion criteria: * having psychiatric illness * native language not turkish

Keywords: endorphin massage cortisol level stress pregnant women
reduction of intrapartum fever with intravenous acetaminophen

Conditions: Fever; Oxidative Stress

Summary: the investigators plan to administer acetaminophen (tylenol) for the treatment of fever in laboring patients by either an oral or intravenous (iv) route. the investigators want to see if the maternal fever will decrease faster with the iv or the oral dose. the investigators also want to look at other outcomes such as the cesarean section rate, the rate of neonatal intensive care unit admissions in both groups.

this is a randomized, controlled, study of intravenous (iv) acetaminophen (ofirmev) versus orally administrated acetaminophen for the reduction of intrapartum maternal fever and fetal tachycardia. compared to oral acetaminophen, intravenous acetaminophen has increased bioavailability and more rapid onset of action. iv acetaminophen has been used successfully in the management of fever in post-operative patients. additionally, intravenous acetaminophen has also been used in the intrapartum setting for management of pain.however, the use of intravenous acetaminophen for the treatment of maternal temperature and subsequent fetal tachycardia, has not yet been evaluated. the study will have two arms that will be randomized in a 1:1 ratio. a double dummy, double blind, comparator controlled study design will be utilized. after inclusion criteria have been satisfied, subjects in the control arm will receive an oral dose 1000 mg acetaminophen and an intravenous placebo resembling ofirmev. the subjects in the experimental arm will receive 1000 mg of iv ofirmev and an oral placebo resembling acetaminophen. both groups will receive standard obstetrical care, continuous fetal monitoring, and antibiotics if there is suspected chorioamnionitis. the blinding technique will eliminate provider bias.

Eligibility criteria:
inclusion criteria: * patients at richmond university medical center that entered active labor (spontaneous or induced) and developed a systemic fever of greater than 38 degrees celsius. exclusion criteria: * exclusion criteria: infants delivered before 36 week gestation, stillbirths, congenital fetal anomalies, scheduled cesarean deliveries, and acetaminophen allergy

Keywords: acetaminophen labor intrapartum fever maternal fever fetal tachycardia intravenous acetaminophen
verification of the efficacy/safety of the mixed drug injectable delivery vehicle for treating intractable hearing loss

Conditions: Hearing Loss, Sensorineural; Hearing Loss, Sudden; Intratympanic Injection

Summary: this study is a prospective, randomized pilot study. to verify an efficacy/safety of the mixed drug injectable delivery vehicle for treating intractable hearing loss. hearing test, endoscopy of tympanic membrane and ct scans will be conducted after intratympanic treatment for evaluation.

the goal of this clinical trial (pilot study) is to evaluate the efficacy and safety of combined hyaluronic acid and dexamethasone treatment in patients with hearing loss. the main questions it aims to answer are: • q1. verification of safety, • q2. therapeutic effect of drug injection on sensorineural hearing loss. participants will undergo several assessment tests (verification of adverse effects in the external and middle ear through endoscopy, confirmation of adverse effects through imaging, hearing test to check for additional hearing loss, check if subjective ear fullness persists for more than a week aside from the drug effect). if there is a comparison group: researchers will compare dexamethasone and hyaluronic acid to verify hearing improvement and safety.

Eligibility criteria:
inclusion criteria: * patients with sudden hearing loss, meniere's disease, ototoxic hearing loss, and noise-induced hearing loss of 25db hl at the frequency at which hearing loss occurs as a result of pure tone hearing test * patients whose original hearing ability has not been restored with existing standard treatment (oral, intravenous steroids) * those who have not participated in clinical trials within 3 months are selected as subjects exclusion criteria: * pregnant or lactating women * when accompanied by lesion, infection, or anatomical deformity of the outer ear, middle ear, or inner ear * those with liver disease or metabolic disease or a history thereof * history of hypersensitivity to indocyanine green or iodine hypersensitivity * history of ear surgery * cases with posterior labyrinth lesions * patients with a history of hypersensitivity to the ingredients of this drug * in addition, serious diseases such as end-stage renal disease, end-stage liver disease, cardiovascular surgery, progressive brain tumor, progressive hemorrhage, and progressive cerebral hemorrhage are included cases with brain disease and cancer are excluded from the study

Keywords: drug delivery dexamethasone hyaluronic acid
inflammatory effects of a lung recruitment manoeuvre

Conditions: Respiratory Insufficiency; Respiratory Distress Syndrome, Adult

Summary: recruitment manoeuvres, consisting of sustained inflations at high airway pressures, have been advocated as an adjunct to mechanical ventilation in lung protective ventilation strategies to prevent the collapse of the lung. this study aims to determine the safety and efficacy of a recruitment manoeuvre, by considering its impact on gas exchange, hemodynamics and on the release of systemic inflammatory mediators.

this prospective study will analyse the effects of a single recruitment manoeuvre in critically ill patients. subjects will be mechanically ventilated patients needing alveolar rms. after a period of stable lung protective approach ventilation, they will receive the "40/30" rm; lung mechanics, gas exchange, hemodynamics and plasmatic concentration of inflammatory mediators will be obtained before and after the rm. an ultrasound score, established from the lung aeration status of upper and lower parts of anterior and lateral chest wall, will also be calculated before and after the manoeuvre.in selected patients cytokine release in the bronchoalveolar lavage will be measured as well.

Eligibility criteria:
inclusion criteria: * mechanical ventilation * arterial catheter inserted * hypoxemic respiratory failure (pa02/fio2 \<300) * radiological evidence of atelectasis or pulmonary infiltrates in the cxr * informed consent exclusion criteria: * elevated intracranial pressure \>25 mmhg * bronchopulmonary fistula * emphysema * kidney or liver failure

Keywords: ards recruitment manoeuvres peep cytokines respiratory insufficiency
a multiple-dose study of sinemet® cr (carbidopa/levodopa) in healthy subjects

Conditions: Parkinson's Disease

Summary: the purpose of this clinical research study is to determine if different dosage regimens of sinemet® cr (carbidopa/levodopa) are dose proportional


Eligibility criteria:
* key inclusion and exclusion criteria for healthy volunteers will be used * males and females aged 50-75
supporting decisions on lifestyle change

Conditions: Obesity

Summary: this study will test the effects of a brief, individually tailored intervention aiming to increase initiation of comprehensive behavioral weight loss treatment on weight.


Eligibility criteria:
inclusion criteria: * age 18 or older * body mass index (bmi) ≥ 30 kg/m2 based on self-report body weight and height, or bmi ≥ 27-29.9 kg/m2 with a weight related comorbidity of hypertension, type 2 diabetes, pre-diabetes, dyslipidemia, or obstructive sleep apnea, gastroesophageal reflux disease, or coronary artery disease. * self-report weight ≤ 375 lbs (the maximum weight that bodytrace scales can accurately detect is 397 lbs, thus 375 lbs provides a buffer to allow detection of at least 20 lbs weight gain). * has a desire to weigh less * has valid email address in electronic health record * has an appointment scheduled with enrolled pcp about 21-28 days after electronic data pull * speaks and reads english * has either wifi internet access at home or a phone or tablet with a data plan. exclusion criteria * currently enrolled in evidence-based comprehensive weight loss treatment * pregnant or planning to become pregnant in the next 6 months * currently breastfeeding (or pumping breastmilk) more than 3 times per day. * currently undergoing treatment for cancer * had cardiovascular event in the past 60 days * severe depression symptoms on phq-8 (total score ≥20) * inpatient psychiatric treatment in the past 6 months * eating disorder in past 5 years * congestive heart failure resulting in recent (past 6 months) hospitalization or contributing to difficulty breathing or difficulty doing daily activities. * dementia diagnosis * bariatric surgery in the past year or currently undergoing evaluation for bariatric surgery * currently taking doctor-prescribed medication for weight loss * inability to stand on body weight scale independently * impaired hearing * unable to read content on websites without assistance

Keywords: initiation recruitment engagement behavioral intervention
evaluation of the benefits of enhanced recovery after surgery (eras) protocol in pelvic prolapse

Conditions: Urinary Incontinence; Pelvic Organ Prolapse

Summary: eras protocols have been shown to improve recovery in terms of reduced pain, shortened time to ambulation and length of hospital stay. this study aims to investigate the impact of eras protocol on time to mobilization and length of hospital stay in patients undergoing surgery for urinary incontinence and pelvic prolapse.

eras protocols containing several preoperative, intraoperative and postoperative measures have been shown to improve recovery in terms of reduced pain, shortened time to ambulation and length of hospital stay in patients undergoing surgery. however, data concerning the role of eras protocols in urogynecological surgery is limited. the present study, therefore, aimed to address the role of eras protocols in patients undergoing surgery for urinary incontinence and pelvic prolapse.

Eligibility criteria:
inclusion criteria: * must be scheduled for surgery because of urinary incontinence or pelvic organ prolapse exclusion criteria: * insulin dependent diabetes
paclitaxel in treating patients with recurrent or persistent cancer of the uterus

Conditions: Sarcoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of paclitaxel in treating patients with recurrent or persistent cancer of the uterus.

objectives: i. estimate the antitumor activity of paclitaxel in patients with metastatic or persistent leiomyosarcoma of the uterus who have failed treatment protocols of higher priority. ii. determine the nature and degree of toxic effects of paclitaxel in this group of patients. outline: patients receive a continuous infusion of paclitaxel once every 3 weeks over 3 hours. patients in complete remission, partial remission, or stable disease undergo at least 3 courses of paclitaxel. paclitaxel continues until disease progression or adverse effects prohibit further treatment. all patients are followed until death. projected accrual: this study anticipates an annual accrual of approximately 25 patients over 2.5 years.

Eligibility criteria:
disease characteristics: histologically confirmed recurrent or persistent uterine leiomyosarcoma that is refractory to curative therapy or established treatments measurable disease required must have failed local therapeutic measures and must be considered incurable not eligible for gog protocols of higher priority patient characteristics: age: not specified performance status: gog 0-3 life expectancy: not specified hematopoietic: wbc at least 3,000/mm3 platelet count at least 100,000/mm3 granulocyte count at least 1,500/mm3 hepatic: bilirubin no greater than 1.5 times normal sgot and alkaline phosphatase no greater than 3 times normal renal: creatinine no greater than 2.0 mg/dl cardiovascular: no unstable angina within 6 months or no myocardial infarction within 6 months abnormal cardiac condition (e.g., bundle branch block, heart block) allowed if stable for 6 months other: no significant infection no concomitant malignancy other than nonmelanomatous skin cancer prior concurrent therapy: at least 3 weeks since prior therapy to malignant tumor biologic therapy: not specified chemotherapy: recovery from prior chemotherapy required no more than 1 prior chemotherapy regimen allowed no prior paclitaxel no prior chemotherapy for any malignancy from which the patient is disease-free for at least 5 years endocrine therapy: not specified radiotherapy: recovery from prior radiation therapy required no prior radiation therapy for any malignancy from which the patient is disease-free for at least 5 years surgery: recovery from prior surgery required

Keywords: recurrent uterine sarcoma uterine leiomyosarcoma
evaluation of three regimens of chemoprophylaxis for tuberculosis in patients co-infected by hiv and mycobacterium tuberculosis

Conditions: HIV Infections

Summary: to evaluate adherence and safety of three regimens of chemoprophylaxis for tuberculosis (tb) in hiv-infected patients with positive tuberculin skin test.

desings: we performed a randomised, comparative and open clinical assay carried out in 316 hiv-infected patients. the patients were randomly assigned to one of three regimens, 108 to isoniazid for six months (6h), 103 to rifampin and isoniazid for three months (3rh), and 105 to pyrazinamide and rifampin for two months (2rz). results: the tb rates (cases per 100 persons/year) in the three treatment groups were 3.4 in 6h, 4.5 in 3rh and 1.9 in 2rz. the relative risk for tb with 6h as compared with 2rz was 1.76, and with 3rh, 2.34. twenty-seven percent of the patients voluntarily abandoned chemoprophylaxis and 9.7% were withdrawn due to adverse side-effects. seven patients were withdraw due to hepatotoxicity (5 in 6h, 2 in 3rh and 0 in 2rz). no appreciable differences were found among the three regimens. conclusion: in our study the 2rz regimen was as safe as the 6h and 3rh regimens. we have nor observed a higher incidence of hepatotoxicity in patients who received 2rz.

Eligibility criteria:
inclusion criteria: * hiv infection confirmed by elisa and western blot * age between 18 and 65 years * life expectancy greater than two years * reactivity to ppd \> 5 mm exclusion criteria: * presence of active tuberculosis * background of previous antituberculosis therapy or chemoprophylaxis * presence of symptoms or signs suggesting pulmonary or extra-pulmonary tuberculosis * history of hypersensitivity to the drugs used in the study (isoniazid, rifampin or pyrazinamide) * aspartate-aminotransferase and/or alanine-aminotransferase plasma concentrations more than or equal to four times their normal values, total bilirubin more than 2 mg/ml, and/or creatinine more than 2 mg/ml * pregnancy * undergoing treatment incompatible with any of the drugs used in the study.

Keywords: hiv tuberculosis prophylaxis aids
bay38-9456, 5/10/20mg, vs.placebo in erectile dysfunction

Conditions: Erectile Dysfunction

Summary: purpose of the study is:- to assess the efficacy and tolerability of vardenafil in male subjects suffering from erectile dysfunction as compared to placebo- to assess the influence of vardenafil on the self-esteem and self-confidence of subjects suffering from erectile dysfunction following treatment with vardenafil as compared to placebo


Eligibility criteria:
inclusion criteria: * men with heterosexual relationships aged 18 - 64 years suffering from ed for more than 6 months according to the nih consensus statement (i.e. inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance). * at least 4 attempts at sexual intercourse (according to the question in the subject diary) on 4 separate days during the 4-week untreated baseline period. at least 50% of attempts during this period had to be unsuccessful according to the subject diary. exclusion criteria: * presence of penile anatomical abnormalities (eg penile fibrosis or peyronie's disease) that in the investigator's opinion would significantly impair sexual performance. * primary hypoactive sexual desire.-spinal cord injury-history of surgical prostatectomy (transurethral interventions not excluded). * unstable angina pectoris. * history of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months. * uncontrolled atrial fibrillation/flutter at screening visit (ventricular response rate \>100 bpm).

Keywords: vardenafil erectile dysfunction sses-e (sexual self-efficacy scale - erectile function)